ArticleAnnals of medicine and surgery (2012)2026
Evaluating the efficacy of recombinant factor VIIa for non-surgical persistent bleeding in cardiovascular surgery: a retrospective cohort study.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent bleeding after cardiovascular surgery challenges hemostatic management, especially in pediatric patients, but recombinant activated factor VIIa (rFVIIa), when used as a procoagulant, may improve patient outcomes. Materials and methods: We retrospectively evaluated 34 cardiac surgery patients who received recombinant rFVIIa for nonsurgical bleeding. Data on patient characteristics, surgical technique, rFVIIa administration, blood product use, complications, and hemostatic evaluation were collected. Red blood cell (RBC) transfusion volumes for 1 hour before and after rFVIIa administration were compared via a paired Results: Nineteen adult patients (mean age, 56.3 ± 15.3 years) and 15 pediatric patients [neonates (birth to 28 days), 7/15; infants (29 days to 1 year), 7/15; and preschoolers (3-6 years), 1/15] were included. RBC transfusion volumes were significantly reduced in adults (mean difference, 192.6 mL; 95% CI, 128.8-256.4 mL; Conclusion: The need for blood transfusion during complex and emergency cardiac surgery was significantly reduced with rFVIIa administration, which was judged effective in the management of bleeding during cardiac surgery. Large-scale trials are needed to optimize its use in cardiac surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.